Related references
Note: Only part of the references are listed.Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)
T. R. Cottrell et al.
ANNALS OF ONCOLOGY (2018)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
P. M. Forde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer
Elizabeth Ahern et al.
ONCOIMMUNOLOGY (2018)
An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer
Alexander Liede et al.
ONCOIMMUNOLOGY (2018)
Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study-NADIM study-SLCG.
Mariano Provencio-Pulla et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Neoadjuvant atezolizumab plus chemotherapy in resectable non-small cell lung cancer (NSCLC).
Catherine A. Shu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).
Valerie W. Rusch et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy
Elizabeth Ahern et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer
Shuan Rao et al.
GENES & DEVELOPMENT (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Current Trends of Lung Cancer Surgery and Demographic and Social Factors Related to Changes in the Trends of Lung Cancer Surgery: An Analysis of the National Database from 2010 to 2014
Samina Park et al.
CANCER RESEARCH AND TREATMENT (2017)
Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice
Elizabeth Ahern et al.
CLINICAL CANCER RESEARCH (2017)
Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities
Kate Roberts et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma
Mark J. Smyth et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2014)
Treatment of Stage I and II Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
John A. Howington et al.
CHEST (2013)
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial)
Virginie Westeel et al.
EUROPEAN JOURNAL OF CANCER (2013)
Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid Subgroup Analysis from a Randomized Phase 3 Study
Giorgio Vittorio Scagliotti et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab
David L. Lacey et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Recent trends in resection rates among non-small cell lung cancer patients in England
Sharma P. Riaz et al.
THORAX (2012)
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non-Small-Cell Lung Cancer
Enriqueta Felip et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Kenneth F. Schulz et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group
Jean-Pierre Pignon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups
Gary M. Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Patterns of surgical care of lung cancer patients
AG Little et al.
ANNALS OF THORACIC SURGERY (2005)
Share Paper
